Home Blog Page 2450

GLOBAL FIRST “High-Definition Image”: Decoding the “Code of Youth” – LivingPhoenix’s POGMENT Collagen Breakthrough Bridges International Gap

CHENGDU, China, Sept. 11, 2025 /PRNewswire/ — Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of “collagen fiber bundles” using Cryo-Electron microscopy (Cryo-EM) under near-physiological and cryogenic conditions. This breakthrough fills the international knowledge gap in understanding collagen’s self-assembly mechanism.

The result was achieved through collaboration with the Cryo-EM platform team at Tianfu Jincheng Laboratory (Frontier Medical Center). Using a 300kV Cryo-TEM (Titan Krios G4), the team captured ultra-structural details across multiple sample batches, with morphology further validated by Talos L120C TEM at room temperature. This marks a major original breakthrough for China in the high-end biomaterials field.

LivingPhoenix Technology’s POGMENT collagen achieves global first high-resolution visualization of “collagen fiber bundles” by Cryo-EM
LivingPhoenix Technology’s POGMENT collagen achieves global first high-resolution visualization of “collagen fiber bundles” by Cryo-EM

POGMENT is the world’s first biomimetic collagen to overcome thermal instability. It is a synthetic material not derived from animals, solving key bottlenecks in structural stability and functional consistency of traditional collagen. The technology originated from an initial process (1.0) at Kyoto University, was introduced to China (v1.1) by Japanese scientists, upgraded locally in Chengdu to v1.2, and finally developed into a second-generation independent intellectual property system (2.0) by a global team of PhDs from the University of Tokyo, Peking University, Chinese Academy of Sciences, and University Paris Dauphine.

The technology has applied for 6 Chinese invention patents applications and 6 PCT applications, with 3 material patents and 1 use patent already granted. Trademark and other IP rights have been registered in the U.S., EU, UK, South Korea, and Japan. Joint original research by LivingPhoenix, Shanghai Ninth People’s Hospital, National Center of Gerontology Beijing Hospital, Peking University Third Hospital, and the University of Tokyo has been peer-reviewed and published in the Q1 SCI journal Frontiers in Bioengineering and Biotechnology (Impact Factor: 4.8).

Furthermore, this technological achievement has been filed with the National Medical Products Administration (NMPA) in accordance with national standards, and has been included in the Terminology for Collagen in Tissue-Engineered Medical Devices (YY/T1955-2025), Medical Device Master File and Cosmetic Ingredient.

For collaboration opportunities in cosmetics, medical aesthetics, or high-end biomaterials, contact:

Email: POGMENT@mylivingphoenix.com 

Official websitewww.mylivingphoenix.com  

TARIFF FEARS DRIVE U.S. STOCKPILING IN AUGUST, WHILE MANUFACTURING WEAKENS IN EUROPE AND ASIA: GEP SUPPLY CHAIN VOLATILITY INDEX

  • North America’s supply chains get busier, with sharp stockpiling of components to guard against tariff-driven shortages and price inflation
  • Asia’s manufacturers cut purchases, led by Japan and Taiwan, and to a lesser extent China
  • Europe weakens further, dragged down by Germany and a sharp downturn in the UK

CLARK, N.J., Sept. 11, 2025 /PRNewswire/ — GEP Global Supply Chain Volatility Index, a leading economic indicator based on a monthly survey of 27,000 businesses, slipped to -0.39 in August, from -0.35 in July, signaling rising spare capacity as global supply chain activity cooled.

The global figure concealed stark regional contrasts. North America was the outlier, with supply chains running close to full capacity as companies in the continent stockpiled raw materials and components to protect against tariff-driven shortages and delivery delays. This was particularly true for the US consumer goods sector, which includes industries such as food & beverages and household products.

By contrast, Asia’s index fell to a three-month low as purchasing activity weakened in China’s consumer non-cyclicals sector, although the region’s weakness was predominantly across Japan and Taiwan. Europe also deteriorated, with Germany’s basic materials sector faltering and UK manufacturing plunging deeper into contraction. The index here (-0.90) signaled one of the steepest declines since 2024.

“So far tariffs have neither spurred growth nor triggered collapse,” said Michael DuVall, GEP’s global head of supply chain strategy. “Tariff uncertainty is no longer a temporary, it’s a structural reality in the supply chain. Companies need to manage it by reinvesting in resilience, diversifying suppliers, and building critical capabilities like demand sensing to make faster, smarter decisions.”

GEP Global Supply Chain Volatility Index
GEP Global Supply Chain Volatility Index

Interpreting the data:
Index > 0, supply chain capacity is being stretched. The further above 0, the more stretched supply chains are.
Index < 0, supply chain capacity is being underutilized. The further below 0, the more underutilized supply chains are.

REGIONAL HIGHTLIGHTS

  • ASIA: Index fell to a three-month low to indicate rising spare capacity across Asia’s supply chains as purchasing volumes in China was flat. In contrast, South Korea, Indonesia and particularly India saw greater factory procurement activity.
  • NORTH AMERICA: Supply chains were practically running at full capacity as recent orders were delivered and companies added to stock.
  • EUROPE: Index falls again as factories purchased fewer intermediate goods and destocked. The data continue to highlight the fragile nature of Europe’s industrial recovery.
  • U.K.: Index falls sharply to -as U.K. manufacturers cutback on procurement and inventories.
GEP Global Supply Chain Volatility Index
GEP Global Supply Chain Volatility Index

Interpreting the data:
Index > 0, supply chain capacity is being stretched. The further above 0, the more stretched supply chains are.
Index < 0, supply chain capacity is being underutilized. The further below 0, the more underutilized supply chains are.

For more information, visit www.gep.com/volatility.

Note: Full historical data dating back to January 2005 is available for subscription. Please contact economics@spglobal.com.

The next release of the GEP Global Supply Chain Volatility Index will be 8 a.m. ET, Oct. 10, 2025.

About the GEP Global Supply Chain Volatility Index 
The GEP Global Supply Chain Volatility Index is produced by S&P Global and GEP. It is derived from S&P Global’s PMI® surveys, sent to companies in over 40 countries, totaling around 27,000 companies. The headline figure is a weighted sum of six sub-indices derived from PMI data, PMI Comments Trackers and PMI Commodity Price & Supply Indicators compiled by S&P Global.

  • A value above 0 indicates that supply chain capacity is being stretched and supply chain volatility is increasing. The further above 0, the greater the extent to which capacity is being stretched.
  • A value below 0 indicates that supply chain capacity is being underutilized, reducing supply chain volatility. The further below 0, the greater the extent to which capacity is being underutilized.

A Supply Chain Volatility Index is also published at a regional level for Europe, Asia, North America and the U.K. For more information about the methodology, click here.

About GEP
GEP® delivers AI-powered procurement and supply chain solutions that help global enterprises become more agile and resilient, operate more efficiently and effectively, gain competitive advantage, boost profitability and increase shareholder value. Fresh thinking, innovative products, unrivaled domain expertise, smart, passionate people — this is how GEP SOFTWARE, GEP STRATEGY and GEP MANAGED SERVICES together deliver procurement and supply chain solutions of unprecedented scale, power and effectiveness. Our customers are the world’s best companies, including more than 1,000 Fortune 500 and Global 2000 industry leaders who rely on GEP to meet ambitious strategic, financial and operational goals. A leader in multiple Gartner Magic Quadrants, GEP’s cloud-native software and digital business platforms consistently win awards and recognition from industry analysts, research firms and media outlets, including Gartner, Forrester, IDC, ISG, and Spend Matters. GEP is also regularly ranked a top procurement and supply chain consulting and strategy firm, and a leading managed services provider by ALM, Everest Group, NelsonHall, IDC, ISG and HFS, among others. Headquartered in Clark, New Jersey, GEP has offices and operations centers across Europe, Asia, Africa and the Americas. To learn more, visit www.gep.com.

About S&P Global
S&P Global (NYSE: SPGI) S&P Global provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make decisions with conviction. From helping our customers assess new investments to guiding them through ESG and energy transition across supply chains, we unlock new opportunities, solve challenges and accelerate progress for the world. We are widely sought after by many of the world’s leading organizations to provide credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help the world’s leading organizations plan for tomorrow, today.

Media Contacts

Derek Creevey                                                           

Joe Hayes

Director, Public Relations                                           

Principal Economist

GEP                                                                           

S&P Global Market Intelligence

Phone: +1 646-276-4579                                             

Phone: +44-1344-328-099

Email: derek.creevey@gep.com                                   

Email: joe.hayes@spglobal.com

 

Locksley Resources Adds 249 Additional Claims to Landholding of More than 40 sq km of Highly Prospective Critical Minerals Ground in California’s Mojave Region

Brings Company’s Total Claims to 491 in Area Housing the Only Rare Earths Producing Mine in U.S.

Move Expands Locksley’s Exploration Pipeline Across Antimony, Rare Earths Elements and Polymetallic Prospects

SAN BERNARDINO, Calif., Sept. 11, 2025 /PRNewswire/ — Locksley Resources Limited (ASX: LKY; OTCQB: LKYRF), announced it has significantly expanded its strategic footprint within the Mojave Critical Minerals Corridor in California through the staking of an additional 249 claims. This brings the company’s total landholding to 491 claims.

The new claims are adjacent to Locksley’s existing tenement position and adjoin MP Materials landholding, which includes the Mountain Pass Rare Earth Mine. The new claims also secure additional acreage for Locksley in that they abut the recently identified antimony, rare earths elements (REEs) and polymetallic mineralization reported by the company.

“These additional claims significantly strengthen Locksley’s competitive positioning within one of the most prospective critical minerals regions in the U.S.,” said Nathan Lude, Head of Strategy, Capital Markets and Commercialization for the company. “With demand for antimony and REEs underpinned by U.S. supply chain security initiatives, the expanded landholding provides Locksley with a broader platform to advance multiple exploration and development opportunities,” he noted.

The south-east claims encompass the favorable gneissic geology, which hosts the Mountain Pass mine and carbonatites. “Significantly there are substantial regional north to north-west striking structures evident in the magnetic geophysics datasets,” said Julian Woodcock, Locksley’s technical director. “These transgress across the areas staked, which conceptually have the potential to host pathways for REE bearing carbonatites and be related to other styles of mineralization,” he said.

Woodcock added that the Northern claims are 3km directly along strike from Dateline Resources Colosseum Gold Project. “In addition, the USGS geochemical database indicates polymetallic and precious metals occurrences in the area immediately adjoining the new northern claims. As such there are multiple commodity opportunities evident within this claim area.”

Lude added, “Importantly, several of the new claims directly adjoin the Mountain Pass larger claim package, underlining the strategic significance of Locksley’s footprint within the corridor. This positioning enhances potential for both exploration discovery and long-term commercialization pathways, including downstream processing partnerships in line with U.S. government priorities for supply chain resilience.”

More information on this can be found at https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02992119-6A1283295&v=c2533a54e2514fb77a8f93f84db686e1125273e9.

Locksley Resources is an Australian-based explorer focused on critical minerals and base metals, with assets in both the U.S. and Australia. The company is actively advancing its U.S. asset, the Mojave Project, in California, targeting rare earth elements (REEs) and antimony. The company has also announced a strategic collaboration with Rice University to develop DeepSolv™, for domestic processing of North American antimony. The agreement is the first step in the initiation of Locksley’s U.S. Critical Minerals and Energy Resilience Strategy to accelerate “mine-to-market” deployment of antimony in the U.S.

Contact: Beverly Jedynak, Beverly.jedynak@viriathus.com, 312-943-1123; 773-350-5793 (cell)

YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC

SHANGHAI, Sept. 11, 2025 /PRNewswire/ — YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech’s clinical programs and global strategic execution.

Dr. Yuxuan Wu, Founder and CEO of YolTech, “This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing science into real-world treatments for patients worldwide.”

About YolTech Therapeutics
Founded in 2021, YolTech Therapeutics is advancing next-generation in vivo gene-editing therapies designed for one-time treatment. The company has built a fully integrated platform encompassing proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a cutting-edge lipid nanoparticle delivery system (Yol-LNPs), enabling precise, efficient, and tissue-specific gene editing across a broad range of therapeutic areas.

In 2024, YolTech’s lead program YOLT-201, a CRISPR-based therapy for transthyretin amyloidosis (ATTR), became the first in vivo gene-editing therapy in China to enter Phase I/IIa clinical trial. Since then, the company has advanced four clinical-stage programs addressing ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD).

YolTech operates a cGMP-compliant manufacturing facility supporting clinical supply through Phase III and early commercial scale-up, ensuring manufacturing consistency and scalability across programs.

With one of the most extensive in vivo gene-editing clinical pipeline globally, YolTech continues to lead in the field. Its base-editing therapy YOLT-101, developed for familial hypercholesterolemia (HeFH), became the first in vivo base-editing program to receive IND clearance in both China and the United States.

 

Commerce Dot Com Wins Double Honours At PIKOM Digital Excellence Awards 2025


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 11 September 2025 – Commerce Dot Com Sdn Bhd (CDC) has achieved a remarkable double victory at the PIKOM Digital Excellence Awards 2025 (PDEA), winning recognition for both its transformative digital solutions and its commitment to cybersecurity. The company was awarded the Outstanding Digital Transformation Project (Corporate Category) which was received by Ministry of Finance (MOF) for its flagship platform, ePerolehan, as well as the coveted Cybersecurity Award.

Executive Chairman of CDC, Syed Azmin Syed Nor (second from right), receiving the Cybersecurity Award from Minister of Digital YB Gobind Singh Deo at the PIKOM Digital Excellence Awards (PDEA) 2025 Gala Dinner in Sunway Resort Hotel.
Executive Chairman of CDC, Syed Azmin Syed Nor (second from right), receiving the Cybersecurity Award from Minister of Digital YB Gobind Singh Deo at the PIKOM Digital Excellence Awards (PDEA) 2025 Gala Dinner in Sunway Resort Hotel.

The ePerolehan system, Malaysia’s official electronic procurement platform under the custodian of MOF, has been at the heart of the nation’s digitalisation journey since its launch in 2000. Over the past 25 years, it has evolved from a pioneer government electronic procurement initiative into a benchmark for large-scale IT transformation, reshaping how government procurement is managed and delivered. Today, ePerolehan connects thousands of suppliers with government agencies, enabling greater transparency, efficiency, and accountability across the public sector.

Winning the Outstanding Digital Transformation Project Award affirms ePerolehan’s pivotal role in advancing Malaysia’s knowledge-based economy through continuous innovation, effective change management, and strong stakeholder engagement. The Cybersecurity Award further underscores CDC’s commitment to resilience, with ePerolehan built on security-by-design principles that safeguard sensitive data and critical infrastructure. In today’s climate of growing cyber threats, these dual recognitions highlight ePerolehan’s enduring impact as a national platform that delivers innovation, reliability, and long-term socio-economic value.

“Digital transformation and cybersecurity are inseparable. Winning both awards is a reminder of our responsibility to lead with innovation while safeguarding trust. Our journey with ePerolehan is far from over – we are committed to building platforms that are future-ready and continue to serve with transparency and resilience.” said Syed Azmin Syed Nor, Executive Chairman of CDC.

The dual awards reflect CDC’s vision that true digital transformation must go hand in hand with robust cybersecurity. By combining cutting-edge innovation with uncompromising standards of trust, CDC has built a platform that supports government, empowers businesses, and benefits citizens nationwide.

Group photo of CDC and MOF at the PDEA 2025 Gala Dinner at Sunway Resort Hotel.
Group photo of CDC and MOF at the PDEA 2025 Gala Dinner at Sunway Resort Hotel.

PDEA 2025, Malaysia’s premier digital excellence awards, honours visionary companies and leaders who are shaping innovation and driving impact across the nation’s tech ecosystem. The awards were chosen by professional jury comprising senior industry experts.

Hashtag: #CDC #CommerceDotCom #PDEA #PIKOM




The issuer is solely responsible for the content of this announcement.

About Commerce Dot Com Sdn Bhd

Commerce Dot Com Sdn Bhd (CDC), established in 1999, pioneered ePerolehan, Malaysia’s electronic government Procurement system under the Ministry of Finance. For 25 years, CDC has driven digital transformation in public procurement, fostering transparency, accountability, and inclusivity, and continues to be a trusted technology partner for the nation.

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

SYDNEY, Sept. 11, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.

In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia’s investigational PI3K–mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a statistically significant reduction in single circulating tumor cells and achieved a complete (100%) disruption of circulating tumor cell (CTC) clusters containing three or more cells.”

Key Points

  • HER2-positive breast cancer accounts for 15–20% of cases and remains a clinical challenge despite the transformative impact of HER2-targeted therapies, with many patients experiencing resistance, recurrence, or metastasis.
  • Immunotherapy has demonstrated success across several solid tumors but has shown limited efficacy in HER2-positive breast cancer, underscoring the need for new therapeutic approaches.
  • In this study, liquid biopsy profiling of Stage IV patients revealed that paxalisib treatment effectively disrupted CTCs and CTC clusters, which are considered biomarkers of aggressive disease and metastasis.
  • Immunofluorescence analyses showed that paxalisib-treated blood samples from HER2-positive mBC patients achieved complete disruption of highly metastatic CTC clusters (≥3 cells).

“This monotherapy ex-vivo result extends our understanding of paxalisib’s potential beyond triple-negative breast cancer into HER2-positive disease,” said Dr. John Friend, CEO of Kazia Therapeutics. “The ability to disrupt circulating tumor cell clusters, which are strongly associated with metastasis and poor prognosis, represents a transformative therapeutic avenue. We are particularly excited by the precision medicine aspect of this work, which leverages biomarkers to both track metastatic burden and guide therapeutic decisions. This work underscores Kazia’s commitment to expanding paxalisib’s utility across multiple subtypes of advanced breast cancer, addressing high unmet need in patients with limited options.”

These findings complement Kazia’s ongoing Phase 1b trial in Stage IV triple-negative breast cancer (TNBC), where initial patient data announced in July 2025 demonstrated significant reductions in circulating tumor cells and clusters, underscoring the broader potential of paxalisib to address metastatic progression across multiple breast cancer subtypes.

Next Steps

Detailed datasets encompassing metastatic signatures and disrupted progenitor populations in Stage IV HER2-positive breast cancer have been submitted for presentation at an upcoming global oncology meeting in 2025.

For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC,  Astarr@lifesciadvisors.com, +1-201-786-8795.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia’s clinical and preclinical trials, including the potential presentation at an oncology conference of comprehensive datasets, including analyses of metastatic signatures and disrupted progenitor populations in Stage IV HER2-positive breast cancer patients, Kazia’s strategy and plans with respect to its paxalisib program, the potential results of its Phase 1b clinical trial evaluating paxalisib in combination with olaparib or pembrolizumab for patients with advanced breast cancer, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

This announcement was authorized for release by Dr John Friend, CEO

EPWK’s Global Transformation Strategy

XIAMEN, China, Sept. 11, 2025 /PRNewswire/ — EPWK (NASDAQ: EPWK), a Nasdaq-listed digital services platform based in Xiamen, has launched its international platform intl.epwk.com, marking a strategic leap from a domestic Chinese operation to a truly global tech company. Founder and CEO Huang Guohua believes that successful internationalisation will unlock new value and global potential for China’s creative service economy.

According to Huang, internationalisation goes far beyond launching an English website. It’s a deep strategic upgrade—a move to optimise growth, improve brand positioning, and expand ecosystem reach. It positions EPWK as a cross-border infrastructure platform aligned with global trends in remote work, service globalisation, and the internationalisation of Chinese brands.

Since going live, the international platform has seen thousands of new users register daily. It is already becoming a key channel for global creative agencies targeting Chinese clients. For EPWK, this global pivot is a chance to unlock higher-value markets—especially in North America and Europe, where the demand for creative and digital services is stronger and client budgets are larger.

International revenue will also reduce dependency on domestic markets and strengthen the company’s financial stability. Analysts see EPWK’s global expansion as a critical move that opens a new growth curve and raises the ceiling on what the company can achieve.

Being publicly listed on Nasdaq further amplifies the need for global reach. A successful international platform boosts investor confidence by proving the company’s business model can scale across borders.

The shift also coincides with a global shift toward remote collaboration, especially post-pandemic. Creative services are naturally suited for distributed work, and EPWK is capitalising on this opportunity—positioning itself at the intersection of digital trade and globally distributed talent.

Team of EPWK
Team of EPWK

With Chinese brands rapidly expanding abroad—across sectors like EVs, electronics, and cross-border e-commerce—there’s growing demand for global-ready design, marketing, and localisation services. EPWK aims to become a critical infrastructure partner supporting this wave of expansion.

Huang outlined EPWK’s dual-sided network strategy: attract high-quality service providers from regions like Southeast Asia, Europe, and the Americas, while also meeting demand from Chinese enterprises going global and foreign SMEs seeking reliable creative talent. The goal is to create a balanced, high-density transaction marketplace.

Challenges remain—cross-cultural operations, global competition, regulatory compliance, and international copyright enforcement. But Huang sees these as necessary battles. Successfully solving them could position EPWK as a category-defining company, setting industry benchmarks and building strong competitive moats.

As of June 30, 2024, EPWK has more than 25.6 million registered users and over $1.67 billion in GMV, covering more than 2,800 cities and counties in China. Since its founding in 2011, EPWK has also played a central role in standard-setting within China’s creative economy, including leading the creation of the country’s first group standard for creative skills platforms.

Aitu Secures AI Product Innovation Gold Award at 2025 IFA, Redefining the Future of Garment Industry

China’s AI-Driven Apparel Innovation Set to Take the International Stage

HANGZHOU, China, Sept. 11, 2025 /PRNewswire/ — With its outstanding strength in applying artificial intelligence (AI) to the field of garment production innovation, Aitu recently received the 2025 IFA AI Product Innovation Gold Award in Berlin, Germany. As one of the world’s top technology exhibitions, this year’s IFA saw fierce competition in AI technology – particularly from Chinese brands, whose rapid rise is reshaping the global tech landscape and marking a milestone for China’s AI innovation.

This honor from IFA not only recognizes Aitu’s strengths in the integration of artificial intelligence with garment smart manufacturing, humanoid robots, and other industrial intelligent manufacturing applications, but also signifies Aitu’s leading position in the race for innovation in the convergence of AI and garment manufacturing industries, demonstrating its increasingly important role on the global stage.

As the premium AI brand developed by Jack Technology (Stock Code: 603337), a global leader in intelligent sewing, Aitu is devoted to developing AI technologies and applying them within intelligent garment production. Building upon AI-driven equipment, the brand is pursuing the research and development of humanoid robots and automated production modules, accelerating the industry’s transition toward labor-light manufacturing.

“In the global wave of industrial intelligence, artificial intelligence is replacing traditional decision-making at lower cost and with greater speed, empowering us to respond with agility to the evolving needs of our customers. AI significantly boosts overall management efficiency, enabling businesses to stay competitive in the fast-paced garment industry,” said Steven Zhang, President of Aitu. “We have achieved a groundbreaking milestone with the initial application of AI technology in B-end industrial manufacturing. Moving forward, we will keep AI as our cornerstone—deepening humanoid robot integration with intelligent apparel equipment and scaling AI-driven manufacturing across production lines worldwide.

Aitu will host its global brand launch at the Shanghai Tower on September 23, 2025. Themed “Al Reinvents Sewing Machine,” the event will showcase Aitu’s AI-powered apparel production solutions, reshaping the landscape of the global manufacturing industry.